Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Deep rTMS for Treatment-Resistant Late-life Depression (rTMS)

This study is ongoing, but not recruiting participants.
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Daniel Blumberger, Centre for Addiction and Mental Health Identifier:
First received: May 18, 2013
Last updated: July 25, 2016
Last verified: July 2016
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left DLPFC. The investigators propose that active stimulation with the H1 coil will result in higher remission rates than placebo stimulation but will have a similar tolerability and safety profile.

Condition Intervention
Major Depressive Disorder
Device: Brainsway H1-Coil Deep TMS System (Sham treatment)
Device: Brainsway H1-Coil Deep TMS System

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Study of H1-Coil rTMS for Treatment-Resistant Late-Life Depression

Further study details as provided by Daniel Blumberger, Centre for Addiction and Mental Health:

Primary Outcome Measures:
  • HDRS-24 [ Time Frame: 4 weeks ]
    Remission defined as HDRS-24 </= 10

Secondary Outcome Measures:
  • Mean change in HDRS-24 [ Time Frame: 4 weeks ]

Estimated Enrollment: 80
Study Start Date: June 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: Sham H1 Coil
deep rTMS sham treatment
Device: Brainsway H1-Coil Deep TMS System (Sham treatment)
In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
Active Comparator: Active H1
deep rTMS active treatment
Device: Brainsway H1-Coil Deep TMS System
Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions

Detailed Description:
This study is a randomized double blind, sham controlled study to evaluate the safety and efficacy of H1-coil rTMS as a treatment for patients over 60 years of age with major depressive disorder who have not tolerated or failed to respond to antidepressant medications. The study duration is 4-6 weeks in length. The acute phase is 4 weeks of 5 daily treatments followed by 2 weeks of biweekly treatment if remission is achieved at the 4 week mark. Symptom change and remission criteria will be assessed using the HRDS-24 item. Cognition will be assessed using a validated battery.

Ages Eligible for Study:   60 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • outpatients
  • voluntary and competent to consent to treatment
  • SCID for DSM-IV confirmed diagnosis of major depressive disorder, single or recurrent
  • between the ages of 60 and 85
  • failed to achieve a clinical response to an adequate dose of an antidepressant based on an ATHF score of ≥ 3 in the current episode OR have been unable to tolerate at least 2 separate trials of antidepressants of inadequate dose and duration (ATHF 1 or 2)
  • a score of ≥ 22 on the HDRS-24
  • no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
  • able to adhere to the treatment schedule
  • pass the TMS safety screening questionnaire
  • have normal thyroid functioning based on pre-study blood work

Exclusion Criteria:

  • history of DSM-IV substance dependence or abuse within the last 3 months
  • concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
  • acutely suicidal
  • pregnant
  • lifetime SCID diagnosis of Bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
  • SCID diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder) assessed by a study investigator to be primary and causing greater impairment than MDD
  • SCID diagnosis of any personality disorder and assessed by a study investigator to be primary and causing greater impairment than MDD
  • have presumed or probably dementia, as defined by Mini Mental Status Exam (MMSE)<26 and clinical evidence of dementia
  • failed a course of ECT within the current depressive episode
  • a significant neurological disorder or insult, including, but no limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except those therapeutically induced by ECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes
  • on a dose of Buprioprion greater than 300mg per day
  • have an intracranial implant(e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
  • if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions , or the therapeutic focus over the duration of the study
  • clinically significant laboratory abnormality, in the opinion of the investigator
  • currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy
  • inability to communicate in English
  • non-correctable clinically significant sensory impairment (i.e cannot hear well enough to cooperate with interview)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01860157

Canada, Ontario
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4
Sponsors and Collaborators
Centre for Addiction and Mental Health
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Daniel M. Blumberger, MD, FRCPC Centre for Addiction and Mental Health
Principal Investigator: Zafiris J Daskalakis, Md, FRCPC Centre for Addiction and Mental Health
  More Information

Responsible Party: Daniel Blumberger, Clinician Scientist, Centre for Addiction and Mental Health Identifier: NCT01860157     History of Changes
Other Study ID Numbers: 107/2011
Study First Received: May 18, 2013
Last Updated: July 25, 2016

Keywords provided by Daniel Blumberger, Centre for Addiction and Mental Health:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders processed this record on May 25, 2017